[ad_1]
Sanofi-aventis Korea has announced that its next generation of basal insulin, TJEZO Solostar (name of the ingredient: insulin glazine, 300 U / mL gene recombination), at the annual conference of the European Diabetes Society (EASD), The results of the CONTROL trial have been published and it has been shown that patients who scored their foot injury could more effectively control their blood glucose levels than those who received an adequate dose under the control of a physician.
According to the TAKE CONTROL study, the number of patients with mean glycosylated hemoglobin (HbA1c) reaching the recommended blood glucose target of less than 7% was higher in self-appropriate patients than in appropriate patients direction of the primary caregiver. The patient also determined the number of patients reaching their nocturnal (fasting) blood glucose goal without hypoglycaemia (<3.0 mmol / L) or with severe hypoglycaemia requiring medical treatment. (67% vs. 58%).
During the study period, the degree of decrease in psychological load was similar in both groups, and the number of patients with a high psychological burden after 24 weeks was lower in patients receiving an adequate dose than among those in charge. 8.5% against 12.2%).
David Russell Jones of the TAKE CONTROL Study, Professor of Diabetes and Endocrinology at the Royal Surry County Hospital of Surrey University, UK "Many diabetics suffer from hypoglycemia, a Major Barrier to Treatment Compliance, "said a TAKE CONTROL study It has been shown that newly developed basic insulin such as Tuzeo helps patients better control their own blood sugar levels. "
In the meantime, the TAKE CONTROL study was conducted on 631 adult type-2 diabetic patients whose glucose levels were not adequately controlled, with Tozeol for 24 weeks. We compared the efficacy and safety of Tuzeo when the patient self-administered titration of the dose and when the person in charge performed it.
<© 2018 메디파나뉴스, 무단 전재 및 배포금지>& # 39; The Korean Medical News Center & # 39; MEDIPANA NEWS
Source link